, Volume 29, Issue 1, pp 192-194
Date: 21 Oct 2009

TNF-blockade in patients with advanced hormone refractory prostate cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Interleukin-6 (IL-6) levels are universally elevated in advanced prostate cancer and these levels increase in proportion to tumor burden and decrease with therapeutic response [14]. Despite this intriguing relationship, a role for IL-6 in prostate cancer progression is unclear. Several pre-clinical studies suggest that IL-6 may be an anti-apoptotic agent and a key growth factor in hormone-refractory prostate cancer (HRPC) [57]. Furthermore, anti-IL-6 antibodies can induce apoptosis and tumor regression in mice bearing human hormone-refractory prostate cancer xenografts [810].

We hypothesized that TNFα-inhibition may block IL-6 production and result in a measurable clinical response in patients with bone metastases and HRPC. A pilot study was initiated to examine the effects of TNFα-blockade (infliximab, Centocor) in patients with treatment-refractory HRPC and painful bone metastases. Six patients with HRPC and painful bone metastases were enrolled and treated with infliximab 5 mg/kg ...